Reta is the core Retatrutide research peptide product from Incline Peps
Contact us today to schedule a consultation for these injections and learn more about how we can help you reach your goal weight
They simply want to look less tired, healthier, firmer, and more refreshed
In a 2026 trial, adults with alcohol use disorder and obesity taking semaglutide clocked in fewer heavy drinking days than those on placebo
Patients asking about it should be told the trial data are real, the drug is on a credible path to FDA review, and the right move is to wait, not to source it through grey channels
Important topics include: Potential drug interactions between GLP-1 medications and DMARDs Monitoring strategies for both conditions Whether weight loss might improve RA symptoms or treatment response Cardiovascular risk reduction strategies Safety considerations including contraindications (personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Patients should not discontinue or modify DMARD therapy based on unproven theories about GLP-1 medications treating RA
